The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective analysis of KRAS, BRAF, and PIK3CA mutational status and EGFR copy number in patients (pts) with locally advanced rectal cancer: A translational substudy of a clinical trial (SAKK 41/07) evaluating the effect of neoadjuvant chemoradiation (CRT) with or without panitumumab.
D. Koeberle
No relevant relationships to disclose
S. Bougel
No relevant relationships to disclose
J. Benhattar
No relevant relationships to disclose
F. Bosman
No relevant relationships to disclose
O. Gautschi
No relevant relationships to disclose
H. Sun
No relevant relationships to disclose
G. Bodoky
No relevant relationships to disclose
R. von Moos
No relevant relationships to disclose
D. Helbling
No relevant relationships to disclose